摘要
To the Editor:Multiple myeloma(MM)is currently considered to be an incurable neoplasm and a systemic disease,and the first line of treatment plays a crucial role in MM patients,since the majority of patients do not survive beyond the first-line treatment.[1]Lenalidomide,a first-line drug in the treatment of MM,is sold as a capsule under the trade name Revlimid®,which is in great demand for an increasing incidence of MM.
基金
The research was supported by the National Science and Technology Major Project of China(No.2017ZX09304023)
the Major Specific Project of Sichuan Province(No.2020YFS0034).
